Kitsiou Spyros, Paré Guy, Jaana Mirou, Gerber Ben
Department of Biomedical and Health Information Sciences, College of Applied Health Sciences, University of Illinois at Chicago, Chicago, United States of America.
Research Chair in Digital Health, Department of Information Technologies, HEC Montréal, Montréal, Canada.
PLoS One. 2017 Mar 1;12(3):e0173160. doi: 10.1371/journal.pone.0173160. eCollection 2017.
Diabetes is a common chronic disease that places an unprecedented strain on health care systems worldwide. Mobile health technologies such as smartphones, mobile applications, and wearable devices, known as mHealth, offer significant and innovative opportunities for improving patient to provider communication and self-management of diabetes.
The purpose of this overview is to critically appraise and consolidate evidence from multiple systematic reviews on the effectiveness of mHealth interventions for patients with diabetes to inform policy makers, practitioners, and researchers.
A comprehensive search on multiple databases was performed to identify relevant systematic reviews published between January 1996 and December 2015. Two authors independently selected reviews, extracted data, and assessed the methodological quality of included reviews using AMSTAR.
Fifteen systematic reviews published between 2008 and 2014 were eligible for inclusion. The quality of the reviews varied considerably and most of them had important methodological limitations. Focusing on systematic reviews that offered the most direct evidence, this overview demonstrates that on average, mHealth interventions improve glycemic control (HbA1c) compared to standard care or other non-mHealth approaches by as much as 0.8% for patients with type 2 diabetes and 0.3% for patients with type 1 diabetes, at least in the short-term (≤12 months). However, limitations in the overall quality of evidence suggest that further research will likely have an important impact in these estimates of effect.
Findings are consistent with clinically relevant improvements, particularly with respect to patients with type 2 diabetes. Similar to home telemonitoring, mHealth interventions represent a promising approach for self-management of diabetes.
糖尿病是一种常见的慢性病,给全球医疗保健系统带来了前所未有的压力。移动健康技术,如智能手机、移动应用程序和可穿戴设备,即所谓的移动医疗(mHealth),为改善患者与医疗服务提供者之间的沟通以及糖尿病的自我管理提供了重大且创新的机会。
本综述的目的是批判性地评估和整合来自多项关于移动医疗干预对糖尿病患者有效性的系统评价的证据,以为政策制定者、从业者和研究人员提供参考。
对多个数据库进行全面检索,以识别1996年1月至2015年12月期间发表的相关系统评价。两位作者独立选择评价、提取数据,并使用AMSTAR评估纳入评价的方法学质量。
2008年至2014年期间发表的15项系统评价符合纳入标准。这些评价的质量差异很大,大多数存在重要的方法学局限性。聚焦于提供最直接证据的系统评价,本综述表明,平均而言,与标准护理或其他非移动医疗方法相比,移动医疗干预至少在短期内(≤12个月)可使2型糖尿病患者的糖化血红蛋白(HbA1c)改善多达0.8%,使1型糖尿病患者改善0.3%。然而,证据总体质量的局限性表明,进一步的研究可能会对这些效果估计产生重要影响。
研究结果与临床上相关的改善一致,特别是对于2型糖尿病患者。与家庭远程监测类似,移动医疗干预是糖尿病自我管理的一种有前景的方法。